These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
952 related articles for article (PubMed ID: 18938236)
1. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells. Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and multidrug resistance reversal activity of dihydroptychantol A and its novel derivatives. Sun B; Yuan HQ; Xi GM; Ma YD; Lou HX Bioorg Med Chem; 2009 Jul; 17(14):4981-9. PubMed ID: 19540127 [TBL] [Abstract][Full Text] [Related]
3. Reversal effect of substituted 1,3-dimethyl-1H-quinoxalin-2-ones on multidrug resistance in adriamycin-resistant K562/A02 cells. Sun LR; Li X; Cheng YN; Yuan HY; Chen MH; Tang W; Ward SG; Qu XJ Biomed Pharmacother; 2009 Mar; 63(3):202-8. PubMed ID: 18818047 [TBL] [Abstract][Full Text] [Related]
4. Substituted tetrahydroisoquinoline compound B3 inhibited P-glycoprotein-mediated multidrug resistance in-vitro and in-vivo. Fang W; Li Y; Cai Y; Kang K; Yan F; Liu G; Huang W J Pharm Pharmacol; 2007 Dec; 59(12):1649-55. PubMed ID: 18053326 [TBL] [Abstract][Full Text] [Related]
5. Reversal effect of a macrocyclic bisbibenzyl plagiochin E on multidrug resistance in adriamycin-resistant K562/A02 cells. Shi YQ; Qu XJ; Liao YX; Xie CF; Cheng YN; Li S; Lou HX Eur J Pharmacol; 2008 Apr; 584(1):66-71. PubMed ID: 18304528 [TBL] [Abstract][Full Text] [Related]
6. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells. Xu HB; Li L; Liu GQ Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169 [TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein-mediated multidrug resistance in vitro by milbemycin compounds in adriamycin-resistant human breast carcinoma (MCF-7/adr) cells. Xiang W; Gao A; Liang H; Li C; Gao J; Wang Q; Shuang B; Zhang J; Yan Y; Wang X Toxicol In Vitro; 2010 Sep; 24(6):1474-81. PubMed ID: 20656007 [TBL] [Abstract][Full Text] [Related]
8. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells. Wang TX; Yang XH Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331 [TBL] [Abstract][Full Text] [Related]
9. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833 [TBL] [Abstract][Full Text] [Related]
10. Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity. Xi GM; Sun B; Jiang HH; Kong F; Yuan HQ; Lou HX Bioorg Med Chem; 2010 Sep; 18(18):6725-33. PubMed ID: 20724170 [TBL] [Abstract][Full Text] [Related]
11. The synergistic reversal effect of multidrug resistance by quercetin and hyperthermia in doxorubicin-resistant human myelogenous leukemia cells. Shen J; Zhang W; Wu J; Zhu Y Int J Hyperthermia; 2008 Mar; 24(2):151-9. PubMed ID: 18283591 [TBL] [Abstract][Full Text] [Related]
12. CJY, an isoflavone, reverses P-glycoprotein-mediated multidrug-resistance in doxorubicin-resistant human myelogenous leukaemia (K562/DOX) cells. Ji BS; He L J Pharm Pharmacol; 2007 Jul; 59(7):1011-5. PubMed ID: 17637197 [TBL] [Abstract][Full Text] [Related]
13. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. Liu ZL; Hirano T; Tanaka S; Onda K; Oka K J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364 [TBL] [Abstract][Full Text] [Related]
14. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells. Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877 [TBL] [Abstract][Full Text] [Related]
15. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide. Wei HL; Wu YJ; Jing T; Bai DC; Ma LF Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281 [TBL] [Abstract][Full Text] [Related]
16. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells. Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169 [TBL] [Abstract][Full Text] [Related]
17. Reversal effects of droloxifene on multidrug resistance in adriamycin-resistant K562 cell line. Li J; Xu LZ; Yao JJ; Guo WJ; Xia P; Chen Y Acta Pharmacol Sin; 2001 Nov; 22(11):1023-7. PubMed ID: 11749795 [TBL] [Abstract][Full Text] [Related]
18. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1. Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Xie P; Shen YF; Shi YP; Ge SM; Gu ZH; Wang J; Mu HJ; Zhang B; Qiao WZ; Xie KM Leuk Res; 2008 Mar; 32(3):475-80. PubMed ID: 17709137 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and evaluation of substituted dibenzo[c,e]azepine-5-ones as P-glycoprotein-mediated multidrug resistance reversal agents. Tang X; Gu X; Ren Z; Ma Y; Lai Y; Peng H; Peng S; Zhang Y Bioorg Med Chem Lett; 2012 Apr; 22(8):2675-80. PubMed ID: 22450134 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]